RenovoRx (NASDAQ:RNXT) Upgraded at Zacks Investment Research

RenovoRx (NASDAQ:RNXTGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports.

According to Zacks, “RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California. “

RenovoRx stock opened at $1.89 on Friday. The company has a fifty day simple moving average of $3.09 and a 200-day simple moving average of $4.50. RenovoRx has a 12-month low of $1.89 and a 12-month high of $16.74.

RenovoRx (NASDAQ:RNXTGet Rating) last released its quarterly earnings data on Wednesday, March 30th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.04. As a group, sell-side analysts forecast that RenovoRx will post -1 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new position in RenovoRx in the third quarter valued at $73,000. Virtu Financial LLC acquired a new position in shares of RenovoRx during the fourth quarter worth about $64,000. Two Sigma Securities LLC purchased a new stake in RenovoRx during the third quarter worth about $108,000. Schonfeld Strategic Advisors LLC purchased a new stake in RenovoRx during the third quarter worth about $125,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in RenovoRx during the third quarter worth about $247,000. Institutional investors own 1.60% of the company’s stock.

RenovoRx Company Profile (Get Rating)

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.

Read More

Get a free copy of the Zacks research report on RenovoRx (RNXT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.